HK1045681B - 可逆含水ph敏感脂化试剂、组合物和应用的方法 - Google Patents

可逆含水ph敏感脂化试剂、组合物和应用的方法 Download PDF

Info

Publication number
HK1045681B
HK1045681B HK02107065.3A HK02107065A HK1045681B HK 1045681 B HK1045681 B HK 1045681B HK 02107065 A HK02107065 A HK 02107065A HK 1045681 B HK1045681 B HK 1045681B
Authority
HK
Hong Kong
Prior art keywords
compound according
compound
group
amine
proteins
Prior art date
Application number
HK02107065.3A
Other languages
English (en)
Chinese (zh)
Other versions
HK1045681A1 (en
Inventor
W-C‧沈
H‧海蒂
Original Assignee
南加利福尼亚大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南加利福尼亚大学 filed Critical 南加利福尼亚大学
Publication of HK1045681A1 publication Critical patent/HK1045681A1/xx
Publication of HK1045681B publication Critical patent/HK1045681B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/54—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
HK02107065.3A 1998-12-10 1999-12-09 可逆含水ph敏感脂化试剂、组合物和应用的方法 HK1045681B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11178498P 1998-12-10 1998-12-10
US60/111,784 1998-12-10
PCT/US1999/029119 WO2000034236A1 (en) 1998-12-10 1999-12-09 REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE

Publications (2)

Publication Number Publication Date
HK1045681A1 HK1045681A1 (en) 2002-12-06
HK1045681B true HK1045681B (zh) 2005-05-20

Family

ID=22340445

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02107065.3A HK1045681B (zh) 1998-12-10 1999-12-09 可逆含水ph敏感脂化试剂、组合物和应用的方法

Country Status (16)

Country Link
US (1) US6590071B1 (https=)
EP (1) EP1137631B1 (https=)
JP (1) JP4637362B2 (https=)
KR (1) KR100676419B1 (https=)
CN (1) CN1168711C (https=)
AR (1) AR021604A1 (https=)
AT (1) ATE265429T1 (https=)
AU (1) AU764035B2 (https=)
CA (1) CA2354142A1 (https=)
DE (1) DE69916885T2 (https=)
EA (1) EA200100652A1 (https=)
ES (1) ES2220141T3 (https=)
HK (1) HK1045681B (https=)
IL (2) IL143578A0 (https=)
TW (1) TWI242000B (https=)
WO (1) WO2000034236A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US8541548B2 (en) * 1999-06-07 2013-09-24 Arrowhead Madison Inc. Compounds and methods for reversible modification of biologically active molecules
US7442764B2 (en) * 1999-06-07 2008-10-28 Mirns Bio Corporation Reversible modification of amine-containing compounds
US7019113B2 (en) * 1999-06-07 2006-03-28 Mirus Bio Corporation Reversible modification of membrane interaction
US20080281041A1 (en) 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US8137695B2 (en) * 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
KR100989647B1 (ko) 2001-09-24 2010-10-26 오레곤 헬스 앤드 사이언스 유니버시티 식습관의 변화
EP1474163A2 (en) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
US8008355B2 (en) * 2002-03-11 2011-08-30 Roche Madison Inc. Endosomolytic poly(vinyl ether) polymers
US8138383B2 (en) * 2002-03-11 2012-03-20 Arrowhead Madison Inc. Membrane active heteropolymers
WO2004048530A2 (en) * 2002-11-22 2004-06-10 Carnegie Mellon University Compositions and methods for the reversible capture of biomolecules
US20040151766A1 (en) * 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
US20050054612A1 (en) * 2003-09-08 2005-03-10 Monahan Sean D. Delivery by labile hydrophobic modification of drugs
US20090074885A1 (en) * 2003-09-08 2009-03-19 Roche Madison Inc. Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells
FR2880627B1 (fr) * 2005-01-07 2007-05-18 Silab Sa Procede d'obtention d'un principe actif pour l'eclat du teint, principe actif obtenu et compositions associees
KR100726281B1 (ko) * 2006-07-31 2007-06-11 (주)아모레퍼시픽 신규 지방산 에스테르 화합물 및 이를 유효성분으로함유하는 당뇨 및 비만치료용 조성물
KR20090091145A (ko) * 2006-10-27 2009-08-26 웨이-치앙 션 지질화된 인터페론 및 이의 용도
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
WO2009059984A2 (en) * 2007-11-06 2009-05-14 F. Hoffmann-La Roche Ag Reversible hydrophobization of antitumor drugs for enhanced first-pass drug uptake

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2962504A (en) * 1960-11-29 Production of maleic anhydride
US5144011A (en) * 1981-06-26 1992-09-01 Boston University Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4480106A (en) * 1981-10-28 1984-10-30 Ciba-Geigy Corporation Process for the preparation of asymmetrically substituted maleic anhydrides, and asymmetrically substituted maleic anhydrides
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4764368A (en) 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4889916A (en) 1985-11-19 1989-12-26 The Johns Hopkins University Protein label and drug delivery system
US4751286A (en) 1985-11-19 1988-06-14 The Johns Hopkins University Protein label and drug delivery system
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5017693A (en) 1987-12-02 1991-05-21 Neorx Corporation Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5066490A (en) 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
US5140013A (en) * 1989-11-28 1992-08-18 Universite Laval Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers
FI101678B1 (fi) * 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5907030A (en) * 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
PL183698B1 (pl) * 1995-03-17 2002-06-28 Novo Nordisk As Pochodna insuliny, kompozycja farmaceutyczna i zastosowanie pochodnej insuliny
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5907530A (en) 1995-08-30 1999-05-25 Samsung Electronics Co., Ltd. Optical pickup device
IL129177A0 (en) * 1996-09-26 2000-02-17 Univ Southern California Methods and compositions for lipidization of hydrophilic molecules
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules

Also Published As

Publication number Publication date
CN1350519A (zh) 2002-05-22
CN1168711C (zh) 2004-09-29
DE69916885D1 (de) 2004-06-03
WO2000034236A1 (en) 2000-06-15
CA2354142A1 (en) 2000-06-15
JP2002531543A (ja) 2002-09-24
AR021604A1 (es) 2002-07-31
HK1045681A1 (en) 2002-12-06
EA200100652A1 (ru) 2001-12-24
EP1137631A1 (en) 2001-10-04
ES2220141T3 (es) 2004-12-01
DE69916885T2 (de) 2005-04-07
JP4637362B2 (ja) 2011-02-23
AU764035B2 (en) 2003-08-07
TWI242000B (en) 2005-10-21
US6590071B1 (en) 2003-07-08
KR20010080749A (ko) 2001-08-22
AU2355600A (en) 2000-06-26
KR100676419B1 (ko) 2007-02-05
ATE265429T1 (de) 2004-05-15
EP1137631B1 (en) 2004-04-28
IL143578A0 (en) 2002-04-21
IL143578A (en) 2006-07-05

Similar Documents

Publication Publication Date Title
CN1168711C (zh) 可逆含水pH敏感脂化试剂、组合物和应用的方法
CN1244376C (zh) 可释放的键和含有该键的组合物
CN1068585C (zh) 用于基因治疗的阳离子类脂
JP6549741B2 (ja) ペグ化ｏｘｍ変異体
CN104302408B (zh) Xten缀合组合物和制造其的方法
EP2673004B1 (en) Hydrophobic modified peptides and their use for liver specific targeting
AU2005205867A1 (en) Transglutaminase mediated conjugation of peptides
CN1323213A (zh) 血－脑屏障治疗
CN1219938A (zh) 亲脂组分和血管活性肠肽片段的缀合物
CN1434725A (zh) 两亲聚合物以及包含两亲聚合物的多肽结合物
JP2018517697A (ja) ペグ化オキシントモジュリン変異体
US20100029903A1 (en) Polypeptide Protracting Tags
CN102933599A (zh) 包含额外的二硫键的人胰岛素
US20190160152A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
TW202321274A (zh) 人類運鐵蛋白受體結合肽
CN114980913B (zh) 非酒精性脂肪性肝病的治疗
MXPA01005746A (en) REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE
CN1684941A (zh) 制备酰化肽的方法
MX2011001167A (es) Conjugados peptido-polimero.
CN1720059A (zh) 新的防止管制物质滥用的持续释放的药学化合物

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111209